Year-end Sale % OFF 
Abstract
BackgroundSurvival outcomes are related to treatment choices in a line of therapy and to treatment sequences across all lines of therapy.ObjectiveThe Real-World Treatment Sequences and Outcomes among Patients with NSCLC (RESOUNDS) study is designed to (1) evaluate treatment sequences used for patients who receive at least two lines of therapy for non-small cell lung cancer (NSCLC) in the United States and (2) evaluate patient outcomes in terms of progression-free and overall survival related to treatment sequencing. Additional objectives include the evaluation of symptoms, comorbidities, and health care resource utilization and costs.MethodsPatients will be censored at loss to follow-up due to leaving the health plan or reaching the end of the study period.ResultsThis study is ongoing.ConclusionsThe RESOUNDS cohort study is a novel approach to building a comprehensive dataset that mimics a prospective observational study using linked patient-level data from four real-world data sources. This study will provide timely information on the sequencing of treatments for patients with NSCLC.
Highlights
Lung cancer is the second most common cancer in the United States and the leading cause of cancer-related death, with an estimated 158,040 Americans dying in 2016 from the disease [1]
The RESOUNDS cohort study is a novel approach to building a comprehensive dataset that mimics a prospective observational study using linked patient-level data from four real-world data sources
The two types of lung cancer are small cell and non-small cell lung cancer (NSCLC)—NSCLC accounts for roughly 83% of cases [2]
Summary
Lung cancer is the second most common cancer in the United States and the leading cause of cancer-related death, with an estimated 158,040 Americans dying in 2016 from the disease [1]. The US Food and Drug Administration recently approved several novel biologic agents (eg, ramucirumab, nivolumab, and pembrolizumab) [3,4,5,6]; as a result, the treatment of NSCLC is rapidly evolving. The appropriate timing and most effective sequence of these new agents in the care of patients remains unknown. Care was delivered in distinct lines of therapy, as it was unknown if the patient would be able to continue treatment over time. With the advent of newer agents demonstrating improved overall survival outcomes in the postprogression setting, providers can consider treatment strategies over time. As novel agents continue to demonstrate improved http://www.researchprotocols.org/2017/10/e195/. Survival outcomes are related to treatment choices in a line of therapy and to treatment sequences across all lines of therapy
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
